Bendamustine-EAM versus R-BEAM after high-dose cytarabine-based induction in newly diagnosed patients with mantle cell lymphoma, a LYSA retrospective study
Domitille Costes-Tertrais
(1)
,
Thomas Hueso
(2, 3)
,
Thomas Gastinne
(1)
,
Catherine Thieblemont
(4, 5, 6)
,
Lucie Oberic
(7)
,
Krimo Bouabdallah
(8)
,
Sylvain Garciaz
(9)
,
Emmanuelle Tchernonog
(10)
,
Caroline Dartigeas
(11)
,
Vincent Ribrag
(12, 13)
,
Patrick Fogarty
(14)
,
Rene-Olivier Casasnovas
(15, 16)
,
Roch Houot
(17, 18)
,
Caroline Delette
(19)
,
Sandra Malak
(20)
,
Luc-Matthieu Fornecker
(21)
,
Rémy Gressin
(22)
,
Gandhi Damaj
(23)
,
Steven Le Gouill
(1)
1
CHU Nantes -
Centre Hospitalier Universitaire de Nantes
2 Université Sorbonne Paris Nord
3 Hôpital Avicenne [AP-HP]
4 Université Paris Diderot, Sorbonne Paris Cité, Paris, France
5 UPD5 - Université Paris Descartes - Paris 5
6 AP-HP - Hopital Saint-Louis [AP-HP]
7 IUCT Oncopole - UMR 1037 - Institut Universitaire du Cancer de Toulouse - Oncopole
8 CHU Bordeaux
9 IPC - Institut Paoli-Calmettes
10 CHU - Hôpital Lapeyronie [Montpellier]
11 CHU Trousseau [Tours]
12 IGR - Institut Gustave Roussy
13 Département d'hématologie [Gustave Roussy]
14 LYSARC - The Lymphoma Academic Research Organisation [Lyon]
15 CHU Dijon - Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand
16 LNC - Lipides - Nutrition - Cancer [Dijon - U1231]
17 Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Ponchaillou]
18 MICMAC - Microenvironment, Cell Differentiation, Immunology and Cancer
19 CHU Amiens-Picardie
20 Hôpital René Huguenin [Saint-Cloud]
21 CHU Strasbourg - Centre Hospitalier Universitaire [Strasbourg]
22 CHUGA - Centre Hospitalier Universitaire [CHU Grenoble]
23 CHU Caen
2 Université Sorbonne Paris Nord
3 Hôpital Avicenne [AP-HP]
4 Université Paris Diderot, Sorbonne Paris Cité, Paris, France
5 UPD5 - Université Paris Descartes - Paris 5
6 AP-HP - Hopital Saint-Louis [AP-HP]
7 IUCT Oncopole - UMR 1037 - Institut Universitaire du Cancer de Toulouse - Oncopole
8 CHU Bordeaux
9 IPC - Institut Paoli-Calmettes
10 CHU - Hôpital Lapeyronie [Montpellier]
11 CHU Trousseau [Tours]
12 IGR - Institut Gustave Roussy
13 Département d'hématologie [Gustave Roussy]
14 LYSARC - The Lymphoma Academic Research Organisation [Lyon]
15 CHU Dijon - Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand
16 LNC - Lipides - Nutrition - Cancer [Dijon - U1231]
17 Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Ponchaillou]
18 MICMAC - Microenvironment, Cell Differentiation, Immunology and Cancer
19 CHU Amiens-Picardie
20 Hôpital René Huguenin [Saint-Cloud]
21 CHU Strasbourg - Centre Hospitalier Universitaire [Strasbourg]
22 CHUGA - Centre Hospitalier Universitaire [CHU Grenoble]
23 CHU Caen
Thomas Hueso
- Fonction : Auteur
- PersonId : 795627
- ORCID : 0000-0003-3354-332X
- IdRef : 242182208
Sylvain Garciaz
- Fonction : Auteur
- PersonId : 754493
- IdHAL : sylvain-garciaz
- ORCID : 0000-0002-0081-1255
Rene-Olivier Casasnovas
- Fonction : Auteur
- PersonId : 784360
- ORCID : 0000-0002-1156-8983
- IdRef : 133937771
Roch Houot
- Fonction : Auteur
- PersonId : 767105
- ORCID : 0000-0003-1729-8213
Steven Le Gouill
- Fonction : Auteur correspondant
- PersonId : 761203
- ORCID : 0000-0001-9840-2128
Résumé
Cytarabine-based immuno-chemotherapy followed by autologous stem cell transplantation (ASCT) consolidation is standard of care for fit patients with Mantle Cell Lymphoma (MCL). BEAM (Carmustine, Etoposide, Aracytine, Melphalan) is among the most frequently used conditioning regimen. Studies comparing BEAM with Bendamustine-EAM (BeEAM) have suggested that patients treated with BeEAM have a better progression-free survival (PFS). We performed a cross-study analysis to better evaluate BeEAM. Thirty-five patients from a retrospective study who received R-DHAP/BeEAM were compared to 245 patients from the LyMa trial (NCT00921414) who all received R-DHAP followed by R-BEAM. PFS and Overall Survival (OS) were estimated using Kaplan-Meier methods. At 2 years there was no difference between R-BEAM and BeEAM in either PFS (84.9% versus 87.9%; p = 0.95) or OS (91.8% versus 94.2%; p = 0.30). Analyses were repeated on a propensity score to reduce biases. Each patient from the BeEAM cohort (n = 30) was matched to three patients from the R-BEAM cohort (n = 90) for age, sex, MIPI score, pre-transplant status disease and rituximab maintenance (RM). PFS and OS at 2 years remained similar between R-BEAM and BeEAM with more renal toxicity in BeEAM group. MCL patients who received R-DHAP induction before ASCT have similar outcome after R-BEAM or BeEAM conditioning regimen.